Maximizing Product Uptake through Co-Promotion with KAKEN PHARMACEUTICAL CO.,LTD.
First written in FY2017-Q1. 4 of 5 entries say "Restated". Latest entry: FY2019.
No other company in this theme has enough history to compare yet.
- FY2019RestatedAnnual report
「Basic Agreement on the Co-promotion of Desalex Tablets 5 mg, Kaken Pharmaceutical Co., Ltd., 2017」
The company continues to list the Desalex joint-promotion agreement with Kaken Pharmaceutical in its contract list. - FY2017RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. entered into a co-promotion agreement with Kaken Pharmaceutical Co., Ltd. for this drug, targeting dermatologists and dermatology institutions, and the two companies worked to promote its early adoption.」
The company continues to promote the early adoption of Desalex through joint promotion with Kaken Pharmaceutical. - FY2017-Q3RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. has entered into a basic memorandum with Kaken Pharmaceutical Co., Ltd. concerning the co-promotion of this drug to dermatologists and dermatology institutions, and the two companies are working to maximize its adoption.」
The company continues to pursue the policy of maximizing adoption of desloratadine formulations through joint promotion with Kaken Pharmaceutical. - FY2017-Q2RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. signed a basic memorandum of understanding in July of the same year with Kaken Pharmaceutical Co., Ltd. concerning co-promotion targeting dermatologists and dermatology institutions for the drug, and the 2 companies will work to maximize adoption.」
Continuing the policy of seeking to maximize adoption of desloratadine through co-promotion with Kaken Pharmaceutical. - FY2017-Q1First statedAnnual report
「In addition, in July 2016 we entered into a basic memorandum of understanding with KAKEN PHARMACEUTICAL CO.,LTD. concerning co-promotion. KAKEN PHARMACEUTICAL CO.,LTD. will promote the product to dermatologists and dermatology clinics. KYORIN Pharmaceutical Co.,Ltd. will seek to maximize product uptake through this co-promotion while continuing to enhance its presence in the priority areas of respiratory medicine and otolaryngology under its FC strategy.」
Co-promotion was introduced with KAKEN PHARMACEUTICAL CO.,LTD. covering dermatology, with the aim of maximizing product uptake alongside the FC strategy.